Mantle Cell Lymphoma

The FDA has approved the first non-covalent Bruton tyrosine kinase inhibitor for the treatment of relapsed or refractory mantle cell lymphoma in adult patients, based on clinical studies conducted with participation by Florida Cancer Specialists & Research Institute.

Recent findings that stratify the use of Bruton tyrosine kinase inhibitors in combination with autologous stem cell transplant were explored during major medical conferences in 2022.

Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.

Yazan Samhouri, MD, discusses his impressions of the TRIANGLE clinical trial presented at the 2022 American Society of Hematology Annual Meeting.

Based on findings from the phase 1/2 BRUIN trial, pirtobrutinib has been approved by the FDA for patients with relapsed/refractory mantle cell lymphoma.

Martin Dreyling, MD, discusses the outcomes of the phase 3 TRIANGLE study evaluating ibrutinib in patients with mantle cell lymphoma.

In an interview with Targeted Oncology, Martin Dreyling, MD, discussed the implications of the findings from the TRIANGLE study in patients with mantle cell lymphoma.

Martin Dreyling, MD, discusses findings from the phase 3 TRIANGLE study of ibrutinib in patients with mantle cell lymphoma.

Phase 3 TRIANGLE results show the efficacy of ibrutinib induction and ibrutinib maintenance in patients with mantle cell lymphoma.

A phase 1/2 trial has revealed the promise of using zilovertamab plus ibrutinib for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

Tycel Phillips, MD, discusses recent changes in the mantle cell lymphoma treatment landscape.

In an interview with Targeted Oncology, Jia Ruan, MD, PhD, discussed the updates in the mantle cell lymphoma space, including understanding molecular pathogenesis and risk stratification for this patient population.

An analysis of data from 2002-2015 shows that for patients with mantle cell lymphoma achieving event-free survival after two years may be a prognostic factor for better overall survival outcomes.

An investigational agent is planned for a phase 1 trial of patients with mantle cell lymphoma after preclinical data showed antitumor activity.

Cyrus M. Kahn, MD, discusses the evolution of the treatment landscape for patients with mantle cell lymphoma.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed the many treatment options available and those that are being examined for patients with mantle cell lymphoma in the second-line setting.

At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.

There have been marked improvements in expected remission and overall survival rates in mantle cell lymphoma even though a cure for this disease remains elusive.

Traditionally, MCL was dichotomized based on the age of the patient and their ability to tolerate intensive therapy, [but] now we have to take into consideration biological differences across patients that go well beyond age, says Andre H. Goy, MD.

Christopher J. Melani, MD, discusses the combination investigated in the ViPOR study of patients with relapsed/refractory or untreated mantle cell lymphoma.

In an interview with Targeted Oncology™, Cyrus M. Khan, MD, discussed new strategies for the treatment of mantle cell lymphoma and needs for the future.

Christopher J. Melani, MD, discusses the results of a trial investigating a combination regimen in a cohort of patients with mantle cell lymphoma.

Frontline treatment with ibrutinib, bendamustine, and rituximab showed a prolongation in progression-free survival along with a good response rate in older patients with mantle cell lymphoma.

Michael Wang, MD, gives a brief overview of the safety and efficacy findings of a phase 1b study evaluating acalabrutinib plus venetoclax and rituximab in patients with mantle cell lymphoma.

The phase 3 ZILO-301 study will evaluate the combination of zilovertamab and ibrutinib in patients with relapsed or refractory mantle cell lymphoma.

Christopher Melani, MD, discusses the unmet needs remaining in the mantle cell lymphoma space.

Ibrutinib combined with bendamustine and rituximab extended the highest progression-free survival rate ever reported for this patient population, in the phase 3 SHINE study.

Study results may indicate for a potential alternative treatment option to address the unmet needs for elderly patients with newly diagnosed mantle cell lymphoma, according to Michael Wang, MD.